In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 47 days of free consultation

 

Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: a 1-year analysis of the REDUCE trial

Session Poster Session 6

Speaker Monica Verdoia

Congress : ESC Congress 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease: Treatment, Revascularization
  • Session type : Poster Session
  • FP Number : P5535

Authors : M Verdoia (Biella,IT), H Suryapranata (Nijmegen,NL), S Damen (Nijmegen,NL), C Camaro (Nijmegen,NL), E Benit (Hasselt,BE), L Barbieri (Novara,IT), S Rasoul (Heerlen,NL), AW Van T Hof (Zwolle,NL), V Roolvink (Zwolle,NL), E Ligtenberg (Hoevelaken,NL), S Postma (zwolle,NL), JJE Kolkman (zwolle,NL), MA Brouwer (Nijmegen,NL), E Kedhi (Nijmegen,NL), G De Luca (Novara,IT)

Authors:
M Verdoia1 , H Suryapranata2 , S Damen2 , C Camaro2 , E Benit3 , L Barbieri4 , S Rasoul5 , AW Van T Hof6 , V Roolvink6 , E Ligtenberg7 , S Postma8 , JJE Kolkman8 , MA Brouwer2 , E Kedhi2 , G De Luca4 , 1ASL Biella Ospedale degli Infermi University of Piemonte Orientale - Biella - Italy , 2Radboud University Medical Centre - Nijmegen - Netherlands (The) , 3Virga Jesse Hospital - Hasselt - Belgium , 4Maggiore Della Carita Hospital, Department of Invasive Cardiology - Novara - Italy , 5Atrium Medical Centre Parkstad - Heerlen - Netherlands (The) , 6Isala Clinics - Zwolle - Netherlands (The) , 7Orbus Neich Medical - Hoevelaken - Netherlands (The) , 8Diagram BV - zwolle - Netherlands (The) ,

Citation:

Background. Gender differences in the thrombotic and bleeding risk have been suggested to condition the benefits of antithrombotic therapies in Acute Coronary Syndrome (ACS) patients, and mainly among those undergoing percutaneous coronary interventions with drug eluting stents (DES). Therefore, the impact of gender on the optimal duration of dual antiplatelet therapy (DAPT) treated is still unclear and was therefore the aim of the present sub-study.

Methods. REDUCE is a prospective, multicenter, randomized, investigator-initiated study, designed to enroll 1500 ACS patients after treatment with the COMBO Dual Stent Therapy, based on a non-inferiority design. Patients were randomized in a 1:1 fashion to either 3 or 12 months of DAPT. Primary study endpoint was a composite of all-cause mortality, myocardial infarction, definite/probable stent thrombosis (ST), stroke, target-vessel revascularization (TVR) and bleeding (BARC II, III, V) at 12 months. Secondary endpoints were cardiovascular mortality and the individual components of the primary endpoint.

Results. From June 2014 to May 2016 300 women and 1196 men were randomized in the trial. Among them 43.7% of females and 51.9% of males were assigned to the 3 months DAPT treatment. Baseline characteristics were well matched between the two arms, but of a lower rate of TIMI flow <3 (p<0.001) and lower systolic blood pressure (p<0.05) among women and a more advanced age (p=0.05) among men receiving a shorted DAPT. At 1 year follow-up, no difference in the primary endpoint was observed according to DAPT duration (females: 6.9% vs 5.9%, HR[95%CI]=1.19[0.48-2.9], p=0.71; males: 8.2% vs 9%, HR[95%CI]=0.92[0.63-1.35], p=0.67). Results were confirmed after correction for baseline differences (females: adjusted HR[95%CI]=1.12[0.45-2.78], p=0.81; males: adjusted HR[95%CI]=0.90[0.61-1.32], p=0.60). Comparable rates of survival, thrombotic (MI, stent thrombosis, TVR, stroke) and bleeding events were observed with the two DAPT strategies, with no impact of gender.

Conclusions. The present study shows that among ACS patients randomized in the REDUCE trial, a 3 months DAPT strategy offers comparable results as compared to a standard 12 months DAPT at 1-year follow-up in both male and female gender.

This content is currently on FREE ACCESS, enjoy another 47 days of free consultation

 



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are